Skip to content

Site logo

Main menu
  • Company
    • Who we are
    • What we do
    • Stories
    • History
    • Sustainability
      • Sustainability overview
      • Philanthropy
      • MSD Medical Outreach Program
      • Impact Venture Fund
      • Transparency disclosures
      • Sustainability resources
    • Leadership
      • Leadership overview
      • Board of directors
      • Executive team
    • Culture & values
      • Culture & values overview
      • Code of conduct, ethics and compliance
    • Diversity and inclusion
    • Policies and positions
    • Suppliers
      • Suppliers overview
      • Supplier registration
      • Supplier help for Ariba
  • Research
    • Research overview
    • Areas of focus
      • Oncology
      • Vaccines
      • Infectious diseases
      • Cardiometabolic and respiratory diseases
      • Immunology
      • Neuroscience
      • Ophthalmology
    • Areas of innovation
      • Data science and artificial intelligence
      • Green and sustainable science
      • Our therapeutic modalities
      • Translational medicine
    • Pipeline
    • Business development and licensing
    • Clinical Trials
      • Clinical trials overview
      • Diversity in clinical trials
    • R&D locations
    • How we invent
    • Meet our scientists
    • Publications
    • Safety data sheets (SDS)
    • Product patents
  • Patients
    • Patients overview
    • Play an active role in your health care
    • Fighting counterfeit medicine
  • Media
    • Media overview
    • News releases
    • Company statements
    • Company fact sheet
  • Investors
    • Investors overview
    • Events and presentations
    • Stock information
  • Careers
researcher in lab

Who we are

Learn more
Contact us

Worldwide See our worldwide locations information

What can we help you find?

Search for:
  1. Media
  2. >
  3. Company statements

Company statements

The information contained in each statement posted on this page was factually accurate on the date it was issued. The company assumes no duty to update the information to reflect subsequent developments. Readers of the statements should not rely upon the information as current or accurate after their issuance dates.

Search:

Filter year:

May 29, 2024

MSD to Acquire EyeBio

May 8, 2024

MSD Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through MSD for Mothers

April 25, 2024

MSD Reaffirms Commitment to Gavi, the Vaccine Alliance, to Supply Low- and Middle- Income Countries with its HPV Vaccine

March 13, 2024

Our Company’s Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region

March 11, 2024

MSD Completes Acquisition of Harpoon Therapeutics, Inc.

January 8, 2024

MSD to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

November 21, 2023

MSD to Acquire Caraway Therapeutics, Inc.

September 11, 2023

MSD Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)

August 10, 2023

MSD Reports Strong Progress on its Commitments to Advancing Access to Health and Operating Responsibly

July 21, 2023

MSD Receives Positive European Union CHMP Opinion for Gefapixant

Items per page

41-50 of 81

Connect with us on social

Twitter icon Facebook icon Linkedin icon Instagram icon YouTube icon
  • MSD Manuals
    Medical information source covering thousands of topics in all fields of medicine
  • Clinical trials
    Learn about our clinical trials and find available studies
  • Impact Report
    Reporting on our commitment to operating responsibly to benefit society
  • MSD for Mothers
    An initiative to create a world where no woman has to die giving life
  • MSD Animal Health
    The global animal health business unit of MSD
  • Contact Us
    If you have a question or need more information about us, find out who you should contact.
  • Forward-looking statement
  • Cookie policy
  • Privacy
  • Terms of use
  • Accessibility
  • Sitemap
Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This website of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept